Glycogen Storage Disease Type Ii clinical trials

Explore recruiting glycogen storage disease type ii clinical trials.

Recruiting glycogen storage disease type ii studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Glycogen Storage Disease Type Ii trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A French multicenter Phase 4 open label extension study of long-term safety and efficacy in patients with Pompe disease who previously participated in avalglucosidase development studies in France

France

Therapeutic use (Phase IV) EU CTIS Study details

An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment-naïve Pediatric Participants with Infantile-Onset Pompe Disease (IOPD)

Spain, Netherlands, Germany, Belgium, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1/2 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Infusion of SPK-3006 in Adults with Late-Onset Pompe Disease

Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An open-label, single-center, exploratory study of the safety and efficacy of avalglucosidase alfa in patients with non-classic Pompe disease aged ≥ 5 years.

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Glycogen Storage Disease Type Ii trials by city

Glycogen Storage Disease Type Ii in Toronto Glycogen Storage Disease Type Ii in Vancouver Glycogen Storage Disease Type Ii in Montreal Glycogen Storage Disease Type Ii in Calgary Glycogen Storage Disease Type Ii in Edmonton Glycogen Storage Disease Type Ii in Ottawa Glycogen Storage Disease Type Ii in Winnipeg Glycogen Storage Disease Type Ii in Quebec City Glycogen Storage Disease Type Ii in Hamilton Glycogen Storage Disease Type Ii in Kitchener Glycogen Storage Disease Type Ii in London Glycogen Storage Disease Type Ii in Halifax Glycogen Storage Disease Type Ii in New York Glycogen Storage Disease Type Ii in Los Angeles Glycogen Storage Disease Type Ii in Chicago Glycogen Storage Disease Type Ii in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease